Phase 2
N=57
The Effect of Cannabidiol in Learning and Memory of Adults
Memory
Bottom Line
View on ClinicalTrials.gov: NCT06074172 ↗Enrolled (actual)
57
Serious AEs
0.0%
Results posted
Mar 2025
Primary outcome: Primary: Sum of Trials (I-V) — 49.09; 47.17 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Cannabidiol (246mg press pill) (Drug); Placebo (246mg press pill) (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Colorado State University
- Primary completion
- Nov 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Sum of Trials (I-V) |
49.09; 47.17 | — |
| PRIMARY Proactive Interference Ratio (PI Ratio) |
1.04; 1.21 | 0.008 sig |
| PRIMARY Retroactive Interference Ratio (RI Ratio) |
0.87; 0.83 | — |
| PRIMARY Total Prose Recall |
27.49; 25.49 | — |
| PRIMARY Montreal Cognitive Assessment Score |
26.31; 26.63 | — |
Summary
The main objectives of this study were to test if a singular dose of Cannabidiol (1) enhances the learning and memory of healthy human subjects, (2) test if Cannabidiol has negative effects on Retroactive and Proactive Interference during learning, (3) and test if demographic factors will influence CBD's modulation of human learning and memory.
Eligibility Criteria
Inclusion Criteria
- Were 18 years of age or older
Exclusion Criteria
- Were pregnant or breast-feeding
- Had been diagnosed with mental illness
- Didn't speak English fluently
- Had severe hearing problems
- Had recreational or opioid drug contaminants in their urine
- Were involved in criminal activity
Data sourced from ClinicalTrials.gov (NCT06074172). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.